Compare · ILMN vs PMD
ILMN vs PMD
Side-by-side comparison of Illumina Inc. (ILMN) and Psychemedics Corporation (PMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and PMD operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.87B, about 622.5x PMD ($40.0M).
- ILMN has hit the wire 24 times in the past 4 weeks while PMD has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for PMD).
- Company
- Illumina Inc.
- Psychemedics Corporation
- Price
- $164.45+0.91%
- $2.68-3.60%
- Market cap
- $24.87B
- $40.0M
- 1M return
- +29.84%
- -
- 1Y return
- +102.77%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 24
- 0
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.
Latest ILMN
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)
- Director Siegel Susan E was granted 2,072 shares, increasing direct ownership by 14% to 16,535 units (SEC Form 4)
Latest PMD
- Psychemedics Releases 2026 Workforce Insights Report
- Psychemedics Releases 2025 Workforce Insights Report
- Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights
- SEC Form 15-12G filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)
- SEC Form 25 filed by Psychemedics Corporation
- Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation
- Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)
- Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation